 |
|
Vaccinating boys against human papillomavirus not cost-effective
October 09, 2009Cervical cancer prevention efforts should prioritize vaccinating pre-adolescent girls and continued cervical cancer screening
Boston, MA -- Persistent infection with high-risk types of human papillomavirus (HPV), a sexually transmitted virus, is known to be a cause of cervical cancer. Current guidelines prioritize HPV vaccination of pre-adolescent girls, which has been shown to be cost-effective in previous studies, but the value of vaccinating boys in the United States has been unclear. In a new study, Harvard School of Public Health (HSPH) researchers found that if vaccine coverage and efficacy are high in girls, a universal recommendation to vaccinate young boys is unlikely to provide comparatively good value for resources, compared with vaccinating girls only.
The study appears online October 9, 2009, in The British Medical Journal and will appear in a later print edition.
The HPV vaccine for boys is already licensed in a number of countries and is currently being considered by the U.S Food and Drug Administration (FDA).
"With the near-term possibility of the HPV vaccine being available to boys in the U.S., policymakers will need to decide whether or not to recommend vaccinating boys," said Jane Kim, assistant professor of health decision science and lead author of the study. "To inform these deliberations, both the incremental health benefits that would accrue with vaccination of boys and girls and the economic costs of the program should be compared to those associated with vaccination of girls alone."
Motivated to inform current decision making, Kim and co-author Sue Goldie, professor of health decision science, evaluated the most current epidemiological, clinical and economic data on HPV infections and cervical disease. Because the most important health benefits (e.g., prevention of cervical cancer) from adolescent HPV vaccination will not be observed for years, and possibly decades, they used computer-based disease models to simulate the course of HPV-related diseases in the U.S. population over time. The analysis looked at the vaccine's potential benefits on a comprehensive set of HPV-related conditions among females and males, including cervical and non-cervical HPV-related cancers, genital warts and juvenile onset recurrent respiratory papillomatosis, a rare but severe respiratory condition usually diagnosed in infancy that may be related to a mother's infection with genital warts.
The results showed that, assuming 75% vaccination coverage and lifelong vaccine protection against cervical disease, routine HPV vaccination of 12-year-old girls was associated with a cost-effectiveness ratio of $40,310 per quality-adjusted life year (QALY), a health metric used to reflect both the excess mortality and reduced quality of life associated with disease. In the U.S., interventions with cost-effectiveness ratios below $50,000 or $100,000 per QALY are informally considered good value for the money. Including boys in the vaccination program had a cost-effectiveness ratio of $290,290 per QALY when compared to vaccinating girls only, exceeding the threshold for good value.
The results were robust across a range of alternative scenarios, such as changes in screening practice, decreased vaccine efficacy in boys, shorter duration of vaccine protection, and the inclusion of other HPV-related outcomes noted above. The authors acknowledge, however, that there are many uncertain factors that can influence the findings. For example, if efficacy against long-term HPV-related diseases in both girls and boys remains high, coverage in girls is low, or the vaccine price is substantially lowered, vaccinating boys looks more attractive.
Since the FDA may consider vaccinating boys in the near future, the findings provide important insight about guidelines regarding what groups to include in routine HPV vaccination recommendations. The authors emphasize, "this analysis does not address decision-making at the individual level; indeed, families who are considering HPV vaccination for an individual boy may consider the vaccine benefits worthwhile in terms of reducing the future risk of genital warts and possibly other health conditions."
While the authors conclude that routine vaccination of boys is unlikely to provide comparative value to other public health interventions vying for resources, they emphasize that the study was conducted from a public health perspective and with the objective of informing general policy recommendations at the population-level. "Based on currently available information, efforts for cervical cancer prevention in the U.S. should focus on HPV vaccination of pre-adolescent girls and continued cervical cancer screening in adulthood," said Kim.
Harvard School of Public Health
The HPV vaccine for boys is already licensed in a number of countries and is currently being considered by the U.S Food and Drug Administration (FDA).
"With the near-term possibility of the HPV vaccine being available to boys in the U.S., policymakers will need to decide whether or not to recommend vaccinating boys," said Jane Kim, assistant professor of health decision science and lead author of the study. "To inform these deliberations, both the incremental health benefits that would accrue with vaccination of boys and girls and the economic costs of the program should be compared to those associated with vaccination of girls alone."
Motivated to inform current decision making, Kim and co-author Sue Goldie, professor of health decision science, evaluated the most current epidemiological, clinical and economic data on HPV infections and cervical disease. Because the most important health benefits (e.g., prevention of cervical cancer) from adolescent HPV vaccination will not be observed for years, and possibly decades, they used computer-based disease models to simulate the course of HPV-related diseases in the U.S. population over time. The analysis looked at the vaccine's potential benefits on a comprehensive set of HPV-related conditions among females and males, including cervical and non-cervical HPV-related cancers, genital warts and juvenile onset recurrent respiratory papillomatosis, a rare but severe respiratory condition usually diagnosed in infancy that may be related to a mother's infection with genital warts.
The results showed that, assuming 75% vaccination coverage and lifelong vaccine protection against cervical disease, routine HPV vaccination of 12-year-old girls was associated with a cost-effectiveness ratio of $40,310 per quality-adjusted life year (QALY), a health metric used to reflect both the excess mortality and reduced quality of life associated with disease. In the U.S., interventions with cost-effectiveness ratios below $50,000 or $100,000 per QALY are informally considered good value for the money. Including boys in the vaccination program had a cost-effectiveness ratio of $290,290 per QALY when compared to vaccinating girls only, exceeding the threshold for good value.
The results were robust across a range of alternative scenarios, such as changes in screening practice, decreased vaccine efficacy in boys, shorter duration of vaccine protection, and the inclusion of other HPV-related outcomes noted above. The authors acknowledge, however, that there are many uncertain factors that can influence the findings. For example, if efficacy against long-term HPV-related diseases in both girls and boys remains high, coverage in girls is low, or the vaccine price is substantially lowered, vaccinating boys looks more attractive.
Since the FDA may consider vaccinating boys in the near future, the findings provide important insight about guidelines regarding what groups to include in routine HPV vaccination recommendations. The authors emphasize, "this analysis does not address decision-making at the individual level; indeed, families who are considering HPV vaccination for an individual boy may consider the vaccine benefits worthwhile in terms of reducing the future risk of genital warts and possibly other health conditions."
While the authors conclude that routine vaccination of boys is unlikely to provide comparative value to other public health interventions vying for resources, they emphasize that the study was conducted from a public health perspective and with the objective of informing general policy recommendations at the population-level. "Based on currently available information, efforts for cervical cancer prevention in the U.S. should focus on HPV vaccination of pre-adolescent girls and continued cervical cancer screening in adulthood," said Kim.
Harvard School of Public Health
Cervical Cancer Current Events and Cervical Cancer News RSS1 disease, not 1 demographic
The Asian continent has nearly four billion people living in 47 different countries, and each of these groups has their own unique set of health issues. But when they come to the United States, they're often lumped into one large demographic: "Asian/Pacific Islander."
Alternatively spliced tissue factor identified as promising new biomarker for aggressive cancers
A recently discovered form of the protein that triggers blood clotting may play a key role in the molecular mechanisms leading to the growth of certain metastatic cancers, according to new research reported by an international team of scientists.
M. D. Anderson redefines screening guidelines for breast, cervical and colorectal cancers
Drawing on years of experience in cancer research and patient care, The University of Texas M. D. Anderson Cancer Center released today the most comprehensive, risk-based screening guidelines publicly available to date for breast, cervical and colorectal cancers.
Study finds delay in follow-up among African-American women receiving abnormal breast finding
A new analysis has identified a significant delay in follow-up times among African-American women after the finding of a suspicious breast abnormality.
UIC study finds girls aware of HPV vaccine's benefits
Contrary to concerns that the human papillomavirus vaccine might promote promiscuity, a national survey of girls and young women found that the majority of respondents did not believe the HPV vaccine protected them against other sexually transmitted infections.
Scientists identify common HPV genotypes in northern India, encourage vaccination
Although a wide spectrum of human papillomavirus is seen across the population of India, HPV-16 and HPV-18 are the most common types and a vaccination targeting these types could eliminate 75 percent of the cervical cancers in the region.
Vaccination and testing for the human papilloma virus could eradicate cervical cancer
Cervical cancer could be eradicated within the next 50 years if countries implement national screening programmes based on detection of the human papilloma virus (HPV), which causes the disease, together with vaccination programmes against the virus, according to a cervical cancer screening expert.
Targeted heat therapy offers new standard treatment option for soft tissue sarcoma
Patients with soft-tissue sarcomas at high risk of spreading were 30% more likely to be alive and cancer free almost three years after starting treatment if their tumours were heated at the time they received chemotherapy, according to new research.
Even in a safety net health system, colorectal cancer screening disparities remain
Colorectal cancer screening rates are much lower among those in a safety net health system compared to the national average, and the number one predictor of screening is a combination of regular visits and insurance access.
Promise of nanodiamonds for safer gene therapy
Gene therapy holds promise in the treatment of a myriad of diseases, including cancer, heart disease and diabetes, among many others.
More Cervical Cancer Current Events and Cervical Cancer News Articles
 |
100 Questions & Answers Abourt Cervical Cancer (100 Questions & Answers about . . .) by Don S. Dizon (Author) The only text to provide both the patient and doctor views, 100 Questions & Answers About Cervical Cancer aims to provide a much needed primer for patients and their families and aims to address the questions most relevant to a woman following a diagnosis of pre-invasive changes or invasive cervical cancer. This text gives up-to-date, authoritative, practical answers to your questions about cervical cancer; not only the diagnosis and treatment of the disease, but also female survivorship. This is an invaluable resource for anyone coping with the physical and emotional turmoil of this disease. |
 |
Crying in the Shower-Cervical Cancer by Pamela Ayer (Author) My book contains my personal story from the day of detection of cervical cancer until the day I became a cancer survivor. |
 |
What Every Woman Should Know about Cervical Cancer by Nenad Markovic (Author), Olivera Markovic (Author) Recent introduction of HPV vaccines has raised hopes for immunization against cervical cancer and for the first time in the history of humanity for eradication of one malignant disease. This new âopportunityâ has changed many current views on cervical cancer prevention, control diagnosis and treatment. Many canons and guidelines became subject of review and many revisions are coming. This book is intended to summarize most of these events and to present them to all women in a language understandable by the eneral public. We expect the book will bring all readers the rationale for optimism and will provide guidance as how to gain knowledge and skills for critical thinking and making an educated decision when it will be necessary in their lives. |
 |
Damaged Goods?: Women Living With Incurable Sexually Transmitted Diseases by Adina Nack (Author) How do women living with genital herpes and/or HPV (human papillomavirus) infections see themselves as sexual beings, and what choices do they make about sexual health issues? Adina Nack, a medical sociologist who specializes in sexual health and social psychology, conducted in-depth interviews with 43 women about their identities and sexuality with regard to chronic illness. The result is a fascinating book about an issue that affects millions around the world, but is all too little discussed. "Damaged Goods?" adds to our knowledge of how women are affected by living with chronic STDs and reveals the stages of their sexual self-transformation. From the anxiety of being diagnosed with an STD to issues of blame and shame, Nack - herself diagnosed with a cervical HPV infection - shows why... |
 |
Beating Cervical Cancer Together Sweatshirt XXX-Large White by Shop Zeus |
 |
Beating Cervical Cancer Together Keychain by Design a Product LLC Text on keychain: Beating Cervical Cancer Together * Durable acrylic key chain is crystal-clear and double-sided so the artwork or message is seen twice. * Sturdy metal ring holds your keys securely. * Full color printed images or messages are included. * If you have new ideas or need help selecting text for your custom keychains please contact us. * Size: 2 1/8" x 3 1/2" (Approx. business card) |
 |
100 Pack Teal Blue Ribbon Temporary Tattoos for Ovarian Cervical Uterine Cancer Awareness by Palmetto Fundraising Show your courage and support! These teal ribbon tattoos are perfect for your next awareness event. These tattoos make great inspirational giveaways. 100 tattoos per package. Teal ribbon design with clear sides. Approximately 1.5" x 2". These cancer awareness favors are perfect for your awareness fundraisers or event. |
 |
Say Something! Help End Cervical Cancer 1 DVD and 1 Resource CD Two Cervical Cancer Survivors say something and save lives Editor Producer: Tamika Felder |
 |
Cervical Cancer Awareness Ribbon Mouse Pad by MyHeritageWear.com The Cervical Cancer Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Cervical Cancer Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Cervical Cancer Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Cervical Cancer (Deadly Diseases and Epidemics) by Juliet Spencer (Author) |
| © 2009 BrightSurf.com |